4D Molecular Therapeutics, Inc. (FDMT) Reports In-Line Q3 EPS

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) reported Q3 EPS of ($1.01), in-line with the analyst estimate of ($1.01).

For earnings history and earnings-related data on 4D Molecular Therapeutics, Inc. (FDMT) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Textron Systems wins $231 million Navy contract for landing craft
• XP Inc. (XP) Tops Q2 EPS by 8c